trending Market Intelligence /marketintelligence/en/news-insights/trending/jgwFRhB2lc6K2LBzBNitig2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

CSL secures regulatory approval in Japan for 2 autoimmune disorder drugs

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


CSL secures regulatory approval in Japan for 2 autoimmune disorder drugs

CSL Ltd. said Japan's Ministry of Health, Labour and Welfare approved two autoimmune disorder medicines, Hizentra and Privigen, for treating a rare autoimmune disorder.

Australia-based CSL's Hizentra and Privigen are now approved in Japan for treating chronic inflammatory demyelinating polyneuropathy, a disorder that targets the peripheral nerves and may cause permanent nerve damage.

Hizentra and Privigen are both immunoglobulins, a protein developed by plasma cells to neutralize bacteria and viruses. Hizentra is administered under the skin, while Privigen is injected into the veins.

According to a March 26 press release, the approval of Hizentra is based on results from a late-stage study, called Polyneuropathy and Treatment with Hizentra, or PATH, while Privigen's approval was supported by the results of both the PATH study and a phase 3 trial, called Privigen Impact on Mobility and Autonomy study, or PRIMA.

Patients' response to Privigen, measured by the ability to walk and perform tasks, was 73% and 61% in the PATH and PRIMA studies, respectively.

The U.S. Food and Drug Administration has approved Privigen and Hizentra to treat patients with chronic inflammatory demyelinating polyneuropathy.